FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

Gotlib J, Reiter A, DeAngelo DJ

Oncologist · 2018

Grade Aregulatory review
DOI ↗PubMed ↗

Key Findings

  • ●FDA approval summary for midostaurin in ASM/SM-AHN/MCL (April 2017)
  • ●56% dose modifications for toxicity; 21% treatment discontinuation

Referenced in (1 disease)

Systemic Mastocytosis
ID: pmid-30115735DOI: 10.1634/theoncologist.2018-0222PMID: 30115735